Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fasudil + bevacizumab
- Development stage
- Unknown
- Lead developer
- Asahi Kasei
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravitreal
01
Overview
A combination therapy consisting of fasudil (a Rho-kinase inhibitor) and bevacizumab (an anti-VEGF monoclonal antibody) administered via intravitreal injection. This combination targets multiple pathways involved in diabetic macular edema (DME). Fasudil inhibits the Rho/ROCK pathway, which is involved in leukocyte adhesion to vascular endothelial cells and subsequent endothelial damage leading to vessel hyperpermeability. Bevacizumab targets vascular endothelial growth factor (VEGF), reducing abnormal vessel formation and vascular leakage. Clinical studies have shown that this combination provides enhanced and prolonged therapeutic effects compared to bevacizumab monotherapy in patients with center-involving DME, including those refractory to anti-VEGF therapy alone.
- Other names
- combined intravitreal bevacizumab and fasudilintravitreal fasudil and bevacizumab
02
Targets
VEGFA (Vascular endothelial growth factor A)ROCK1 (Rho-associated coiled-coil containing protein kinase 1)ROCK2 (Rho-associated coiled-coil containing protein kinase 2)
Beyond the preview
Go deeper on fasudil + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fasudil + bevacizumab.